<DOC>
	<DOCNO>NCT01050153</DOCNO>
	<brief_summary>This study plan learn prevent blood clot vein extremity . You risk form clot major injury surgery hospitalize bed rest . Usually , patient SICU Denver Health risk blood clot receive preventative treatment FDA-approved medicine call Fragmin . Fragmin intend prevent blood clot form , way generally use , patient may still develop blood clot . All patient treat Fragmin prevent blood clot Denver Health , currently receive Fragmin dose . This treatment call `` standard care '' . So far , US , commonly available test tell u : - standard dose Fragmin enough prevent blood clot everyone , - different patient need different dos , - blood clot prevent medicine , work different way , use addition Fragmin . The ability blood clot strength clot form described FDA-approved blood test call thrombelastography , refer TEG . TEG may provide u answer question . Our preliminary data indicate helpful assess clot bleed tendency may prove useful guiding treatment prevention blood clot . The aim study determine treatment plan use Fragmin , , indicate , one two additional FDA-approved medicine call anti-platelet drug , guide result TEG test , may better prevent blood clot current standard care .</brief_summary>
	<brief_title>The Clinical Utility Thrombelastography Guiding Prophylaxis Venous Thromboembolism Following Trauma</brief_title>
	<detailed_description>This preliminary/pilot study involve prospective , randomize , open-label , parallel group comparison Denver Health 's current standard care prevention venous thromboembolism ( VTE ) , commonly know blood clot , use LMWH ( Fragmin ) 5000IU subcutaneously daily , thrombelastography ( TEG ) -guided , algorithm-based , individualized regimen LMWH ( Fragmin ) plus/minus anti-platelet therapy ( aspirin ) guide platelet mapping , patient admit SICU follow trauma . Approximately 50 trauma patient prevention VTE LMWH indicate , enrol six month period . The specific aim study follow : 1 . To determine incidence , characterize , hypercoagulability use TEG conventional clinical coagulation test ( APTT , INR ) , Antithrombin III level Protein C activity . 2 . In group patient receive LMWH ( Fragmin ) therapy alone prevention VTE : 1. ass anticoagulant effect standard LMWH ( Fragmin ) dosing ( 5000IU subcutaneously daily ) use TEG Anti-Factor Xa level measurement , 2. determine extent correlation relevant TEG parameter measure Anti-Factor Xa level ( U/ml ) . 3 . To assess whether TEG useful clinical tool monitoring optimize prophylactic LMWH ( Fragmin ) therapy identify need anti-platelet therapy minimize risk VTE patient . 4 . To evaluate clinical utility platelet map guide anti-platelet therapy patient indicate TEG result . 5 . To determine incidence deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) randomize group subgroup receive anti-platelet therapy addition LMWH ( Fragmin ) prevention VTE . The overall aim utilize data evaluate ) adequacy standard Fragmin dose regimen ( 5000IU subcutaneously daily ) alone prevention VTE trauma/SICU patient , b ) need anti-platelet agent addition LMWH ( Fragmin ) prevention VTE population , c ) validate/further develop TEG-guided algorithm optimal prophylaxis VTE use LMWH ( Fragmin ) plus/minus anti-platelet therapy guide platelet mapping .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>age least 18 year , blunt penetrate trauma require admission SICU requirement LMWH ( Fragmin ) therapy prophylaxis VTE standard care , inform consent patient , legally authorize representative proxy decision maker ( patient incompetent provide ) obtain document . Presence follow absolute contraindication LMWH ( Fragmin ) therapy : know hypersensitivity dalteparin sodium , know hypersensitivity heparin pork product , thrombocytopenia associate positive test antiplatelet antibody presence Fragmin , history heparininduced thrombocytopenia ( HIT ) , chronic liver disease ( bilirubin &gt; 2 mg/dl ) kidney insufficiency ( CrCl &lt; 30mL/min ) , intravascular thrombolytic therapy within 24 hour , resuscitation require massive transfusion ( &gt; 10 unit RBC within 6 hour ) , ongoing resuscitation hemorrhagic shock , know bleed disorder coagulopathy ( INR &gt; 2 warfarin ) , thrombocytopenia ( platelet &lt; 20K/uL ) , subdural epidural hematoma . Or Presence follow relative contraindication LMWH ( Fragmin ) therapy : new intracranial lesion , neoplasms monitoring device , extravascular thrombolytic therapy , severe uncontrolled hypertension , arterial dissection recent ( within 12 hour ) intraocular surgery ( prior plan ) , recent ( within 72 hour ) intracranial spine surgery ( prior plan ) , condition associate increase risk hemorrhage , e.g . active gastrointestinal ulceration , angiodysplastic disease , gastrointestinal bleeding within past six month , bacterial endocarditis , history hemorrhagic stroke , diabetic retinopathy . Or Presence , removal within last 12 hour , indwell epidural spinal catheter , OR recent ( within last 12 hour ) plan neuraxial ( spinal/epidural ) anesthesia spinal puncture . Or Per history take patient family , concomitant know use within one week prior hospitalization , drug affect hemostasis NSAIDS , platelet inhibitor anticoagulant , except specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Prevention venous thromboembolism</keyword>
</DOC>